After seeing POC data, Kyowa advances Parkinson’s program despite being dropped by Lundbeck

Kyowa Hakko Kirin has posted (PDF) a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients. The data emboldened Kyowa to commit to a larger phase 2 trial, despite its one-time partner Lundbeck walking away from the program.